molecules of the month

compound 5g

oral CDK2 Inhibitor

oral/IV PK observed in rats

in-house HTS and scaffold hopping

ACS Med. Chem. Lett.

Incyte Research Institute, Wilmington, DE

Compound 5g chemical structure oral CDK2 Inhibitor - Incyte Research Institute, Wilmington, DE
4 mins read

Context. “Compound 5g” (Incyte) is a selective cyclin-dependent kinase 2 (CDK2) inhibitor. Although CDK2 is a highly pursued cancer drug target, inhibitors targeting the key cell cycle regulator have not enjoyed similar success as CDK4/6 inhibitors, in part due to the major challenge of mitigating off-target CDK1/9 activity through the use of highly selective agents. Given recent data suggesting that resistance to approved CDK4/6 inhibitors may involve a CDK2-mediated compensatory pathway, CDK2 inhibitors may additionally address an unmet need for patients who progress following CDK4/6 therapy. Scaffold hopping on an HTS hit led to “compound 5g” containing the 5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one core structure. The compound demonstrated high selectivity (>200x) for CDKs 1/4/6/7/9 and showed submicromolar in vitro activity. Currently, the most advanced…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: